比较[68Ga]Ga-PSMA-11与[18F]PSMA-1007在复发性前列腺癌诊断中的临床性能与成本效益:马尔可夫链决策分析
本研究回顾性分析244例因复发性前列腺癌行PSMA PET/CT的患者(每种放射性药物各122例),采用马尔可夫链决策分析建模比较[68Ga]Ga-PSMA-11与[18F]PSMA-1007的临床性能和成本效益。结果显示[18F]PSMA-1007的PET阳性率非显著更高(91.8% vs 86.9%,p=0.68),但不确定发现率显著更高(17.2% vs 8.25%,p=0.02);[68Ga]Ga-PSMA-11的真阳性概率和PPV更高,成本效益分析在四个司法管辖区中的三个(瑞士、以色列、澳大利亚)支持[68Ga]Ga-PSMA-11。
要点
- [18F]PSMA-1007的PET阳性率91.8% vs [68Ga]Ga-PSMA-11的86.9%(p=0.68),差异未达统计学显著。
- [18F]PSMA-1007的不确定发现率17.2% vs [68Ga]Ga-PSMA-11的8.25%(p=0.02),显著更高。
- 成本效益分析在瑞士、以色列、澳大利亚三个司法管辖区支持[68Ga]Ga-PSMA-11,在丹麦支持[18F]PSMA-1007。
核心结论
- 分析显示[18F]PSMA-1007的PET阳性率非显著高于[68Ga]Ga-PSMA-11,但与[68Ga]Ga-PSMA-11相比,不确定发现率和假阳性发现率显著更高。
- 两种放射性示踪剂在临床性能和成本效益方面存在差异。
- 本文提出的方法具有可推广性,可用于其他国家或示踪剂的临床或成本数据。
研究设计与样本
- 回顾性分析244例因复发性前列腺癌行PSMA PET/CT的患者,[68Ga]Ga-PSMA-11与[18F]PSMA-1007各122例,用于生成PET阳性、阴性和不确定发现的率。
- 患者接受随访以确定额外检查率并确认PET发现。
- 实施马尔可夫链决策分析以建模临床决策过程并分析两种示踪剂的临床性能。
- 使用来自两种放射性示踪剂均常规使用的多个国家的成本数据确定其临床成本效益。
主要发现
- [18F]PSMA-1007的PET阳性率为91.8%,[68Ga]Ga-PSMA-11为86.9%(p=0.68),[18F]PSMA-1007非显著更高。
- [18F]PSMA-1007的不确定发现率为17.2%,[68Ga]Ga-PSMA-11为8.25%(p=0.02),[18F]PSMA-1007显著更高。
- 真阳性发现的概率[68Ga]Ga-PSMA-11为0.90(95%CI 0.70-0.98),[18F]PSMA-1007为0.81(95%CI 0.66-0.91)。
- [68Ga]Ga-PSMA-11的PPV为0.99(95%CI 0.99-1.0),[18F]PSMA-1007为0.86(95%CI 0.82-1.00),差异显著(p<0.0001)。
- 干预效能分析支持[68Ga]Ga-PSMA-11,达到真阳性发现所需的检查人数为10.58,达到假阳性发现所需的伤害检查人数为-8.08。
关键数值与推荐
- 成本效益分析在四个可获取卫生经济学数据的司法管辖区中的三个(瑞士、以色列、澳大利亚)支持[68Ga]Ga-PSMA-11,在一个司法管辖区(丹麦)支持[18F]PSMA-1007。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Amongst others, [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 are available for the detection of recurrent prostate cancer (rPC). There are currently limited data comparing the performance of these two radioligands with respect to clinical outcomes or their cost efficacy, which this study aims to address. METHODS: Two hundred and forty-four patients undergoing PSMA PET/CT for rPC were retrospectively analysed for this study (one hundred and twenty two with each radiopharmaceutical) to generate rates of PET positivity, negativity and unclear findings. Patients underwent follow-up to determine the rate of additional examinations and to confirm PET findings. A Markov chain decision analysis was implemented to model clinical decision-making processes and to analyse clinical performance of the two tracers. We determine their clinical cost efficacies using cost data from several countries where both radiotracers are in routine use. RESULTS: The PET positivity rate was non-significantly higher for [18F]PSMA-1007 compared to [68Ga]Ga-PSMA-11 (91.8% vs. 86.9%, p = 0.68), whereas the rate of uncertain findings was significantly greater (17.2% vs. 8.25%, p = 0.02). The probability of a true positive finding was higher for [68Ga]Ga-PSMA-11 (0.90, 95% CI 0.70-0.98) vs. [18F]PSMA-1007 (0.81, 95% CI 0.66-0.91). A significantly (p < 0.0001) higher PPV for [68Ga]Ga-PSMA-11 (0.99, 95% CI 0.99-1.0 vs. 0.86) was found compared to [18F]PSMA-1007 (0.86, 95% CI 0.82-1.00). Intervention efficacy analysis favoured [68Ga]Ga-PSMA-11, where the number needed to image (to achieve a true positive finding) was 10.58 and the number needed to image to harm (to achieve a false positive finding) was - 8.08. A cost efficacy analysis favours [68Ga]Ga-PSMA-11 in three of the four jurisdictions analysed where health economic data was available (Switzerland, Israel, Australia) and [18F]PSMA-1007 in one jurisdiction (Denmark). CONCLUSION: The analysis reveals a non-significantly higher PET positivity rate for [18F]PSMA-1007, but finds significantly greater rates of uncertain findings and false positive findings when compared to [68Ga]Ga-PSMA-11. We find differences in the two tracers in terms of clinical performance and cost efficacy. The method presented herein is generalisable and can be used with clinical or cost data for other countries or tracers.
引用
- Alberts I, Mingels C, Zacho HD, et al. Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis. Eur J Nucl Med Mol Imaging. 2021. PMID: 34773473. doi:10.1007/s00259-021-05620-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。